Tiff Advisory Services LLC Raises Stock Position in The Oncology Institute, Inc. $TOI

Tiff Advisory Services LLC lifted its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 22.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,634,465 shares of the company’s stock after buying an additional 655,324 shares during the period. Oncology Institute comprises 1.8% of Tiff Advisory Services LLC’s holdings, making the stock its 10th largest position. Tiff Advisory Services LLC owned approximately 4.07% of Oncology Institute worth $7,451,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Josh Arnold Investment Consultant LLC bought a new stake in Oncology Institute during the first quarter worth about $2,267,000. Geode Capital Management LLC grew its stake in Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after purchasing an additional 893,696 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Oncology Institute during the 1st quarter worth approximately $131,000. WealthShield Partners LLC bought a new stake in shares of Oncology Institute during the 1st quarter worth approximately $80,000. Finally, Kingswood Wealth Advisors LLC bought a new stake in shares of Oncology Institute during the 2nd quarter worth approximately $132,000. Institutional investors own 36.86% of the company’s stock.

Insider Buying and Selling

In other Oncology Institute news, Director Growth I. L.P. M33 sold 6,018,168 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the transaction, the director directly owned 7,932,389 shares of the company’s stock, valued at $24,511,082.01. This represents a 43.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on TOI shares. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of Oncology Institute in a research note on Tuesday, October 21st. Noble Financial assumed coverage on shares of Oncology Institute in a research note on Wednesday, July 23rd. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Oncology Institute Trading Down 10.2%

Shares of Oncology Institute stock opened at $3.08 on Friday. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.62 and a quick ratio of 1.37. The business has a fifty day simple moving average of $3.74 and a two-hundred day simple moving average of $3.32. The Oncology Institute, Inc. has a 1 year low of $0.13 and a 1 year high of $4.88. The company has a market capitalization of $288.00 million, a price-to-earnings ratio of -4.53 and a beta of 0.07.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $136.56 million during the quarter, compared to analyst estimates of $122.63 million. Oncology Institute had a negative net margin of 14.26% and a negative return on equity of 1,527.21%. Oncology Institute has set its FY 2025 guidance at EPS.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.